Trump pharma tariffs and the US drug supply chain through 2026: Section 232, Ireland exposure, and the API reshoring arithmetic

The Section 232 pharmaceuticals investigation: scope, timing, and the 25 to 200 percent corridor #

BIS at Commerce published a Federal Register notice on April 16, 2025 commencing a Section 232 investigation of pharmaceuticals and pharmaceutical ingredients under the Trade Expansion Act of 1962. The investigation followed first quarter 2025 Executive actions that imposed reciprocal tariffs at 10 percent on most trading partners and explicitly carved pharmaceuticals out pending the dedicated 232 finding. The statutory clock gives Commerce 270 days to report and a further 90 days for Presidential action, putting an outside decision date in early 2026. The President publicly stated rates between 25 percent and as high as 200 percent through April and August 2025, with industry counsel reading the working range as 15 to 25 percent on finished dose plus a separate, possibly larger, charge on APIs and key starting materials.

Three legal architectures are in scope. Section 232 produces a flat ad valorem duty through HTS revisions and CBP collection, similar to the steel and aluminum stack at 50 percent. The IEEPA basis, used for the early 2025 reciprocal tariffs, provides faster timing but has been challenged at the Court of International Trade and the Federal Circuit. Section 301 of the Trade Act of 1974 against China for forced technology transfer remains an additional vector. The consequential design question is whether the duty is collected on intrafirm transfer price, third party invoice, or constructed value, and whether finished dose, biologic drug substance, biologic drug product, and API rate stacks differ. PhRMA filed for finished dose carve outs and staged implementation; the Association for Accessible Medicines argued any duty flowing through retail generic prices will accelerate withdrawals from low margin molecules and worsen the FDA shortage list.

The 213 billion import stack: where US chapter 30 imports actually come from #

US Census trade data for HTS chapter 30 (Pharmaceutical Products) totalled approximately 213 billion US dollars in calendar 2024. Ireland was the largest source at roughly 50 billion, reflecting biologics and small molecule finished dose manufacturing at Pfizer Grange Castle and Ringaskiddy, Eli Lilly Kinsale, BMS Cruiserath, Merck (MSD) Carlow and Brinny, AbbVie Ballytivnan, Johnson and Johnson Cork, and AstraZeneca Dublin. Switzerland followed at roughly 19 billion (Novartis, Roche, Lonza), Germany at 17 (Boehringer Ingelheim, Bayer, BioNTech), then Singapore, India, and the Netherlands. China and Hong Kong ranked between 8th and 10th in finished dose chapter 30 value but are dominant in HTS chapter 29 (organic chemicals, key APIs) and chapter 38 (intermediates), where the asymmetry lives.

API origin data is murkier because chapter 30 captures finished forms while APIs and key starting materials clear under chapters 29 and 38. FDA Commissioner testimony to House Energy and Commerce in 2019 and 2023 cited that 80 percent of API volumes used in US generic dispensing were sourced from India and China, with India dominant in finished generic dose and China dominant in upstream KSM and intermediates. EFPIA and the European Fine Chemicals Group publish parallel estimates in the 70 to 80 percent range. India's DGFT and Pharmexcil placed Indian pharmaceutical exports to the US at 8.7 billion US dollars in fiscal 2024, dominated by Sun Pharmaceutical, Dr Reddy's, Aurobindo, Lupin, Cipla, and Zydus.

Reshoring capex: 200 billion of announcements, two years of permitting #

Between February and August 2025 the largest US headquartered manufacturers responded to the 232 investigation and the IRA Section 70 Production Incentive (an advanced manufacturing investment credit tracked by the Tax Foundation) with five year US capex announcements aggregating above 200 billion. Eli Lilly announced 27 billion in February 2025 across four new sites, on top of 23 billion deployed from 2020 through 2024 at Lebanon and Concord Indiana, Research Triangle Park North Carolina, and Boone County Indiana, anchoring tirzepatide (Mounjaro and Zepbound) and parenteral biologics. Johnson and Johnson announced 55 billion over four years in March 2025, focused on Wilson North Carolina biologics fill finish and Pennsylvania, New Jersey, and Indiana sites. Novartis announced 23 billion in April 2025 across radioligand therapy and biologics. Pfizer's Made in America program points to roughly 50 billion over five years, anchored by McPherson Kansas, Kalamazoo Michigan, and Sanford North Carolina.

The numbers are large but the binding constraints are physical, not financial. FDA pre approval inspection cycles for new sterile injectable and biologic sites typically run 24 to 36 months from groundbreaking to commercial release; biologic monoclonal antibody and GLP 1 process validation is longer than small molecule. Even on schedule, the share of US dispensed prescription volumes manufactured domestically shifts only marginally before 2028. BARDA at ASPR has used Project BioShield and Industrial Base Expansion authority to support advanced API manufacturing at Phlow Corporation in Petersburg Virginia, API Innovation Center in St Louis, and the National Resilience network, but the volumes remain small relative to the 80 percent India and China API base. The IRA Section 70 PIE, at the rates floated by House Ways and Means in 2024, would offer up to 25 percent investment credit on qualifying pharmaceutical capex, partially offsetting the cost disadvantage versus India and China but not closing the gap on standard generics.

IRA Year 2 negotiated prices and the branded margin compression overlay #

CMS published the second Medicare Part D negotiation list under the Inflation Reduction Act on January 17, 2025, naming 15 drugs whose negotiated maximum fair prices apply from January 1, 2027. The list includes Novo Nordisk's semaglutide franchise (Ozempic, Wegovy, Rybelsus), Boehringer Ingelheim and Lilly's Tradjenta and Jardiance, Pfizer's Ibrance and Xtandi co-promoted with Astellas, AstraZeneca's Calquence, Pfizer's Vyndaqel and Vyndamax, Otsuka and Lundbeck's Rexulti, Novartis's Tasigna, and others. The first list, with prices effective January 1, 2026, covered Eliquis, Xarelto, Januvia, Jardiance, Enbrel, Imbruvica, Stelara, Farxiga, Entresto, Fiasp, and NovoLog, with negotiated reductions between 38 and 79 percent versus 2023 list price.

The interaction with Section 232 is the central commercial issue for 2026 and 2027. A 25 percent finished dose tariff at the border on an intrafirm transfer price for a branded product whose Medicare net price is fixed by negotiation produces direct margin compression that cannot be passed through. For drugs like Mounjaro or Ozempic, where the Medicare negotiated price sits well below current commercial net, the manufacturer's incentive shifts toward US manufacturing for Medicare facing supply and Irish or other ex US manufacturing for commercial facing supply, but FDA chemistry, manufacturing, and controls rules make this segmentation difficult. PhRMA modeling submitted to the 232 docket projects that a 25 percent tariff on Irish finished dose would generate roughly 12 to 14 billion dollars of annual incremental cost for the seven largest manufacturers, of which 60 to 70 percent would be absorbed at the manufacturer level given price ceilings under the IRA, 340B, the Medicaid Drug Rebate Program, and Medicare Part B ASP plus 6 percent.

Generic drug shortages: how a tariff stacks on top of an already broken system #

The FDA Drug Shortages database reported 130 to 150 active shortages across most of 2024 and into Q1 2026, near the highest sustained level since the agency began publishing the list in 2012. ASHP, which maintains a parallel and slightly broader list, reported 277 active shortages in early 2024, the largest on record. Sterile injectable oncology agents (cisplatin, carboplatin, methotrexate), local anesthetics, intravenous fluids and saline (worsened by Hurricane Helene's impact on Baxter's North Cove North Carolina plant in late 2024), and pediatric oncology agents have been the structurally tight categories. The Lown Institute and the USP Drug Supply Map show that more than 80 percent of essential medicine API and finished dose volume in the US traces to facilities outside the country, with India and China dominant.

A 25 percent tariff applied to generic finished dose at retail prices below 5 dollars per prescription does not move retail price meaningfully (on a 4 dollar Walmart generic, the duty is roughly 1 dollar), but it decisively changes the economics for manufacturer and wholesaler. Generic manufacturers operating at gross margins below 20 percent on essential medicines have repeatedly exited categories rather than absorb cost. Sandoz's 2023 exit from selected oral cephalosporins, Akorn's 2023 bankruptcy, and Teva's 2024 to 2025 portfolio rationalization are the recent precedents. Hospital GPOs (Vizient, Premier, HealthTrust) contract three to five years out and have already begun renegotiating with Indian and Chinese sources via cost plus pricing or escape clauses tied to the 232 final action. The Federal Reserve H.8 series on commercial bank lending to drug wholesalers and the BLS Producer Price Index for pharmaceutical preparation manufacturing (NAICS 325412) will be the two leading indicators of pass through once the 232 outcome is set.

2026 to 2028 corridor: scenarios, buyer playbook, and the India ADR signal #

Three scenarios anchor the next 24 months. In the base case, Commerce reports the 232 finding in Q4 2025 or Q1 2026 with a graduated stack: 15 percent on finished dose from non FTA partners, 25 percent on APIs from China specifically, and exemptions or quotas on Ireland and Switzerland tied to bilateral commitments. In the upside reshoring case, Commerce pairs the duty with a quota plus rebate architecture similar to the 2018 Korean steel arrangement, layered on top of the IRA Section 70 PIE, generating accelerated US capacity build and partial offset for hospitals via a budget neutral 340B mechanism. In the downside case, the duty lands at 25 percent or higher across origins without carve outs, FDA shortages compound, and the political response forces emergency 232 pauses and waivers, mirroring the 2018 to 2019 steel quota cycle. Tax Foundation modelling and Peterson Institute analyses center on the base case but assign meaningful probability to each tail.

For procurement and finance leadership, the 2026 playbook has four elements. First, GPO contracts should be reopened with explicit tariff pass through clauses indexed to CBP collected duties on HTS chapters 29 and 30 lines. Second, hospital pharmacy directors should review Lown Institute and USP Drug Supply Map exposure for the top 100 essential medicines and run a scenario where 5 to 10 percent of those molecules become unavailable in 2027. Third, branded pharma finance should model IRA Year 1 plus Year 2 negotiated price compression alongside the 232 transfer price impact and decide whether to accelerate capex from 2027 to 2026. Fourth, generics finance should model BLS PPI pass through versus retailer reimbursement formulae (Generic Effective Rate at large PBMs, Maximum Allowable Cost at Medicaid managed care plans). Indian pharma ADRs (Dr Reddy's RDY) and Reg S accessed listings (Sun Pharmaceutical, Lupin) priced a 10 to 20 percent revenue at risk discount in late 2025; further compression depends on whether the 232 stack lands at the upper or lower bound.

Sources #

• Bureau of Industry and Security, Section 232 Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients, Federal Register notice April 16, 2025
• Office of the United States Trade Representative, 2025 Trade Policy Agenda and 2024 Annual Report
• United States Census Bureau, Foreign Trade, US Imports HTS Chapter 30 by Country, 2024
• Food and Drug Administration, Drug Shortages Database
• Centers for Medicare and Medicaid Services, Medicare Drug Price Negotiation Program, Second Cycle Drug List, January 17, 2025
• American Society of Health System Pharmacists, Drug Shortages Statistics
• Eli Lilly press release, 27 billion US manufacturing investment, February 26, 2025
• Johnson and Johnson press release, 55 billion US investment, March 21, 2025
• Novartis press release, 23 billion US investment, April 10, 2025
• Pfizer Annual Report on Form 10 K 2024
• India Ministry of Commerce and Industry, Directorate General of Foreign Trade, Pharmaceuticals Export Promotion Council (Pharmexcil) annual data
• Bureau of Labor Statistics, Producer Price Index, Pharmaceutical Preparation Manufacturing (NAICS 325412)
• Federal Reserve, Assets and Liabilities of Commercial Banks in the United States, H.8 release
• Tax Foundation, Section 232 tariff modelling and pharmaceutical reshoring analyses 2025
• Peterson Institute for International Economics, US trade policy and pharmaceutical tariff analyses
• Biomedical Advanced Research and Development Authority (BARDA), Industrial Base Expansion contract notices
• United States Pharmacopeia, Drug Supply Map and Medicine Supply Map analyses
• Lown Institute, Drug shortages and supply chain research
• Pharmaceutical Research and Manufacturers of America (PhRMA), Section 232 docket comments 2025
• Association for Accessible Medicines, Section 232 docket comments and generic supply chain analyses